Universe Pharmaceuticals Inc Cash Flow Conversion Efficiency
Universe Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Universe Pharmaceuticals Inc (UPC) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.61 Million) by net assets ($56.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Universe Pharmaceuticals Inc (2018–2025)
Cash flow conversion efficiency of Universe Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Universe Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Universe Pharmaceuticals Inc (UPC) share price today for real-time trading data and today's change.
Universe Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Universe Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Universe Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Universe Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Universe Pharmaceuticals Inc (UPC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
0.030x |
|
Carr's Group plc
LSE:CARR
|
0.075x |
|
Blockchaink2 Corp
V:BITK
|
0.129x |
|
Magnum Goldcorp Inc
V:MGI
|
0.167x |
|
Kooth plc
LSE:KOO
|
0.316x |
|
MAPSPEOPLE A/S DK-02
F:70R
|
N/A |
|
Real Messenger Corporation Ordinary Shares
NASDAQ:RMSG
|
-0.084x |
|
E2Gold Inc
V:ETU
|
0.011x |
Annual Cash Flow Conversion Efficiency for Universe Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Universe Pharmaceuticals Inc from 2018 to 2025. Review UPC free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $56.13 Million | $-5.05 Million | -0.090x | +56.92% |
| 2024-09-30 | $45.50 Million | $-9.51 Million | -0.209x | -837.39% |
| 2023-09-30 | $39.53 Million | $1.12 Million | 0.028x | +200.27% |
| 2022-09-30 | $46.44 Million | $-1.31 Million | -0.028x | +18.99% |
| 2021-09-30 | $58.93 Million | $-2.06 Million | -0.035x | -111.87% |
| 2020-09-30 | $20.80 Million | $6.12 Million | 0.294x | -72.43% |
| 2019-09-30 | $12.38 Million | $13.20 Million | 1.066x | +131.67% |
| 2018-09-30 | $9.68 Million | $4.46 Million | 0.460x | -- |
About Universe Pharmaceuticals Inc
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong … Read more